Synthetic biology company Bota Bio (Enhe Biotechnology) announced the completion of a Series B funding round exceeding $100 million, with existing shareholder Source Code Capital continuing to increase its stake.
Accelerating the design and production of high-performance, sustainable products through synthetic biology.









